Literature DB >> 11506496

Frequency of PSA-mRNA-bearing cells in the peripheral blood of patients after prostate biopsy.

N Hara1, T Kasahara, T Kawasaki, V Bilim, Y Tomita, K Obara, K Takahashi.   

Abstract

Transrectal ultrasound (TRUS) guided prostate biopsy is standard diagnostic procedure for prostate cancer (PCa). However, possibility of dissemination of cancer cells by biopsy is not negligible. To investigate this possibility, we examined prostate specific antigen (PSA)-bearing cells in peripheral blood of the 108 patients before and after prostate biopsy. Peripheral blood samples were obtained from 108 patients with elevated serum PSA (sPSA) levels, who had undergone sextant prostate biopsy using TRUS. The presence of PSA-mRNA bearing cells was examined using the nested RT-PCR method enabling detection of one LNCaP cell diluted in 1 ml of whole blood. Among 108 patients, 62 and 46 were diagnosed with benign prostatic hyperplasia (BPH) and PCa, respectively. PSA-mRNA was detected in 3 PCa cases but in no BPH patients before and after biopsy, and in 16 BPH (25.8%) and in 21 PCa (45.7%) patients only after biopsy (P< 0.01). The patients with positive mRNA before biopsy had higher sPSA (P< 0.001), and those after biopsy had higher sPSA and PSA density (PSAD) levels (P< 0.05). Positive PSA-mRNA cases had more cancer involved biopsy cores than the negative PSA-mRNA cases (P< 0.001). Although further investigations are needed, the present findings suggest that prostate biopsy might scatter prostate cells in the blood stream especially in cases with high sPSA and, thus, might contribute to tumour spreading in the cases of prostate cancer. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11506496      PMCID: PMC2364088          DOI: 10.1054/bjoc.2001.1924

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Cancer statistics digest. Comparison of crude and age-standarized death rates in Japan.

Authors:  S Yamamoto
Journal:  Jpn J Clin Oncol       Date:  1999-12       Impact factor: 3.019

Review 2.  Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction.

Authors:  S L Su; A L Boynton; E H Holmes; A A Elgamal; G P Murphy
Journal:  Semin Surg Oncol       Date:  2000 Jan-Feb

3.  Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer.

Authors:  T Okegawa; H Noda; M Kato; A Miyata; K Nutahara; E Higashihara
Journal:  Prostate       Date:  2000-08-01       Impact factor: 4.104

4.  The significance of hematogenous tumor cell clumps in the metastatic process.

Authors:  L A Liotta; M G Saidel; J Kleinerman
Journal:  Cancer Res       Date:  1976-03       Impact factor: 12.701

5.  Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence.

Authors:  A Mejean; G Vona; B Nalpas; D Damotte; N Brousse; Y Chretien; B Dufour; B Lacour; C Bréchot; P Paterlini-Bréchot
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

6.  Cancer statistics, 2001.

Authors:  R T Greenlee; M B Hill-Harmon; T Murray; M Thun
Journal:  CA Cancer J Clin       Date:  2001 Jan-Feb       Impact factor: 508.702

7.  Detection of circulating tumor cells by reverse transcriptase polymerase chain reaction of maspin in patients with breast cancer undergoing conventional-dose chemotherapy.

Authors:  R Sabbatini; M Federico; M Morselli; R Depenni; K Cagossi; M Luppi; G Torelli; V Silingardi
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

8.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

9.  Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) following radical prostatectomy.

Authors:  A de la Taille; C A Olsson; R Buttyan; M C Benson; E Bagiella; Y Cao; M Burchardt; D K Chopin; A E Katz
Journal:  Int J Cancer       Date:  1999-08-20       Impact factor: 7.396

10.  Blood-based RT-PCR assays of MN/CA9 or PSMA: clinical application in renal cancer patients.

Authors:  A de la Taille; A Katz; Y Cao; J McKiernan; R Buttyan; M Burchardt; T Burchardt; O Hayek; C A Olsson; D K Chopin; I S Sawczuk
Journal:  Urology       Date:  2000-09-01       Impact factor: 2.649

View more
  7 in total

1.  [Metastasis of prostate carcinoma to the lamina submucosa of the distal rectum in ulcerative colitis 2 years after transrectal prostate biopsy and radical prostatovesiculectomy].

Authors:  J Bernhardt; C Letzkus; M Kind; H B Reith; N Pfitzenmaier
Journal:  Urologe A       Date:  2005-01       Impact factor: 0.639

Review 2.  Detection and isolation of circulating tumor cells in urologic cancers: a review.

Authors:  Robert D Loberg; Yaron Fridman; Brian A Pienta; Evan T Keller; Laurie K McCauley; Russell S Taichman; Kenneth J Pienta
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

Review 3.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

4.  The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.

Authors:  Richard E Kast; Nicolas Skuli; Samuel Cos; Georg Karpel-Massler; Yusuke Shiozawa; Ran Goshen; Marc-Eric Halatsch
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-07-11

5.  Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer.

Authors:  Hideyasu Tsumura; Takefumi Satoh; Hiromichi Ishiyama; Ken-Ichi Tabata; Kouji Takenaka; Akane Sekiguchi; Masaki Nakamura; Masashi Kitano; Kazushige Hayakawa; Masatsugu Iwamura
Journal:  Int J Mol Sci       Date:  2017-01-11       Impact factor: 5.923

Review 6.  A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis.

Authors:  Dmitry Enikeev; Andrey Morozov; Diana Babaevskaya; Andrey Bazarkin; Bernard Malavaud
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

7.  Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Authors:  Richard E Kast; Nicolas Skuli; Georg Karpel-Massler; Guido Frosina; Timothy Ryken; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2017-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.